// App-Quantinova.ai

P113 : Nonacog Beta Pegol For The Prophylactic Treatment of Children With Haemophilia B: Interim Results From The Paradigm™ 5 Clinical Trial

Researchers

Presenter

  • M. Carcao

Principal Investigators

  • M. Khodaie

  • S. Ehrenforth

  • F. Abdul Karim

  • M. Taki

  • S. Kearney

  • M.-Y. Lu

  • E. Santagostino

Medical Centers

  • Division of Haematology/Oncology and Child Health Evaluative Sciences, Research Insititute, Hospital for Sick Children, Toronto, ON, Canada

  • Novo NordiskA/S, Soborg, Denmark

  • Novo Nordisk, Zurich, Switzerland

  • Haemophilia Center, National Blood Centre, Kuala Lumpur, Malaysia

  • Department of Pharmacy, St.Marianna University School of Medicine, Kawasaki, Japan

  • Hemophilia Treatment Center, Children's Hospital and Clinics of Minnesota, Minneapolis, United States

  • National Taiwan University Hospital, Children's and Women's Hospital, Taipei, China

  • Angelo Bianchi Bonomi Haemophilia andThrombosis Center. IRCCS Ca Granda Foundation,Maggiore Hospital, Milan, Italy

Locations

  • Canada

  • Denmark

  • Switzerland

  • Malaysia

  • Japan

  • United States

  • China

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Shire, Baxalta

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved